StockNews.com upgraded shares of OpGen (NASDAQ:OPGN – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning.
OpGen Price Performance
OPGN opened at $0.70 on Tuesday. The firm has a 50 day moving average price of $1.10 and a 200 day moving average price of $0.98. The company has a market cap of $3.86 million, a PE ratio of -0.05 and a beta of -0.20. OpGen has a 1 year low of $0.55 and a 1 year high of $16.40. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.88 and a current ratio of 1.01.
OpGen (NASDAQ:OPGN – Get Rating) last issued its quarterly earnings data on Wednesday, March 29th. The medical research company reported ($1.90) earnings per share (EPS) for the quarter. The firm had revenue of $0.72 million during the quarter. OpGen had a negative net margin of 1,429.56% and a negative return on equity of 120.63%. Sell-side analysts expect that OpGen will post -3.83 earnings per share for the current year.
Institutional Inflows and Outflows
OpGen Company Profile
OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm’s also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms.
- Get a free copy of the StockNews.com research report on OpGen (OPGN)
- How to Calculate Stock Growth
- 7 Best Retail Stocks to Invest in
- 3 Home Improvement Stocks to Renovate Your Portfolio
- Beam Global Shines Brightly in the EV Infrastructure Space
- Canoo Bottoms As Production Ramp Gets Closer
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.